Nanomedicines for the delivery of biologics

John Wahlich, Arpan Desai, Francesca Greco, Kathryn Hill, Arwyn T. Jones, Randy Mrsny, Gianfranco Pasut, Yvonne Perrie, F. Philipp Seib, Leonard W. Seymour, Ijeoma F. Uchegbu

Research output: Contribution to journalArticle

Abstract

A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. The challenges in delivering such molecules were discussed with specific emphasis on the delivery both across and into cells. The latest developments in Molecular Envelope Technology® (Nanomerics Ltd), liposomal drug delivery (both from an academic and industrial perspective), opportunities offered by the endocytic pathway, delivery using geneticaly engineered viral vectors (PsiOxus Technologies), Transint™ technology (Applied Molecular Transport), which has the potential to deliver a wide range of macromolecules, and AstraZeneca’s initiatives in mRNA delivery were covered with a focus on their uses in difficult to treat diseases, including cancers. Preclinical data were presented for each of the technologies and where sufficiently advanced, plans for clinical studies as well as early clinical data. The meeting covered the work in progress in this exciting area and highlighted some key technologies to look out for in the future.
LanguageEnglish
Article number210
Number of pages14
JournalPharmaceutics
Volume11
Issue number5
DOIs
Publication statusPublished - 3 May 2019

Fingerprint

Nanomedicine
Biological Products
Technology
Pharmaceutical Preparations
Focus Groups
Intravenous Infusions
Nanoparticles
Small Interfering RNA
Lipids
Messenger RNA
Neoplasms

Keywords

  • nanomedicines
  • drug delivery
  • siRNA
  • mRNA
  • DNA
  • proteins
  • lipid nanoparticles
  • liposomes
  • viral vectors
  • endocytosis

Cite this

Wahlich, J., Desai, A., Greco, F., Hill, K., Jones, A. T., Mrsny, R., ... Uchegbu, I. F. (2019). Nanomedicines for the delivery of biologics. Pharmaceutics, 11(5), [210]. https://doi.org/10.3390/pharmaceutics11050210
Wahlich, John ; Desai, Arpan ; Greco, Francesca ; Hill, Kathryn ; Jones, Arwyn T. ; Mrsny, Randy ; Pasut, Gianfranco ; Perrie, Yvonne ; Seib, F. Philipp ; Seymour, Leonard W. ; Uchegbu, Ijeoma F. / Nanomedicines for the delivery of biologics. In: Pharmaceutics. 2019 ; Vol. 11, No. 5.
@article{a576a803485a4547a624a26b0d6907df,
title = "Nanomedicines for the delivery of biologics",
abstract = "A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. The challenges in delivering such molecules were discussed with specific emphasis on the delivery both across and into cells. The latest developments in Molecular Envelope Technology{\circledR} (Nanomerics Ltd), liposomal drug delivery (both from an academic and industrial perspective), opportunities offered by the endocytic pathway, delivery using geneticaly engineered viral vectors (PsiOxus Technologies), Transint™ technology (Applied Molecular Transport), which has the potential to deliver a wide range of macromolecules, and AstraZeneca’s initiatives in mRNA delivery were covered with a focus on their uses in difficult to treat diseases, including cancers. Preclinical data were presented for each of the technologies and where sufficiently advanced, plans for clinical studies as well as early clinical data. The meeting covered the work in progress in this exciting area and highlighted some key technologies to look out for in the future.",
keywords = "nanomedicines, drug delivery, siRNA, mRNA, DNA, proteins, lipid nanoparticles, liposomes, viral vectors, endocytosis",
author = "John Wahlich and Arpan Desai and Francesca Greco and Kathryn Hill and Jones, {Arwyn T.} and Randy Mrsny and Gianfranco Pasut and Yvonne Perrie and Seib, {F. Philipp} and Seymour, {Leonard W.} and Uchegbu, {Ijeoma F.}",
year = "2019",
month = "5",
day = "3",
doi = "10.3390/pharmaceutics11050210",
language = "English",
volume = "11",
journal = "Pharmaceutics",
issn = "1999-4923",
number = "5",

}

Wahlich, J, Desai, A, Greco, F, Hill, K, Jones, AT, Mrsny, R, Pasut, G, Perrie, Y, Seib, FP, Seymour, LW & Uchegbu, IF 2019, 'Nanomedicines for the delivery of biologics' Pharmaceutics, vol. 11, no. 5, 210. https://doi.org/10.3390/pharmaceutics11050210

Nanomedicines for the delivery of biologics. / Wahlich, John; Desai, Arpan ; Greco, Francesca ; Hill, Kathryn ; Jones, Arwyn T. ; Mrsny, Randy ; Pasut, Gianfranco ; Perrie, Yvonne; Seib, F. Philipp; Seymour, Leonard W.; Uchegbu, Ijeoma F.

In: Pharmaceutics, Vol. 11, No. 5, 210, 03.05.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanomedicines for the delivery of biologics

AU - Wahlich, John

AU - Desai, Arpan

AU - Greco, Francesca

AU - Hill, Kathryn

AU - Jones, Arwyn T.

AU - Mrsny, Randy

AU - Pasut, Gianfranco

AU - Perrie, Yvonne

AU - Seib, F. Philipp

AU - Seymour, Leonard W.

AU - Uchegbu, Ijeoma F.

PY - 2019/5/3

Y1 - 2019/5/3

N2 - A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. The challenges in delivering such molecules were discussed with specific emphasis on the delivery both across and into cells. The latest developments in Molecular Envelope Technology® (Nanomerics Ltd), liposomal drug delivery (both from an academic and industrial perspective), opportunities offered by the endocytic pathway, delivery using geneticaly engineered viral vectors (PsiOxus Technologies), Transint™ technology (Applied Molecular Transport), which has the potential to deliver a wide range of macromolecules, and AstraZeneca’s initiatives in mRNA delivery were covered with a focus on their uses in difficult to treat diseases, including cancers. Preclinical data were presented for each of the technologies and where sufficiently advanced, plans for clinical studies as well as early clinical data. The meeting covered the work in progress in this exciting area and highlighted some key technologies to look out for in the future.

AB - A special symposium of the Academy of Pharmaceutical Sciences Nanomedicines Focus Group reviewed the current status of the use of nanomedicines for the delivery of biologics drugs. This meeting was particularly timely with the recent approval of the first siRNA-containing product Onpattro™ (patisiran), which is formulated as a lipid nanoparticle for intravenous infusion, and the increasing interest in the use of nanomedicines for the oral delivery of biologics. The challenges in delivering such molecules were discussed with specific emphasis on the delivery both across and into cells. The latest developments in Molecular Envelope Technology® (Nanomerics Ltd), liposomal drug delivery (both from an academic and industrial perspective), opportunities offered by the endocytic pathway, delivery using geneticaly engineered viral vectors (PsiOxus Technologies), Transint™ technology (Applied Molecular Transport), which has the potential to deliver a wide range of macromolecules, and AstraZeneca’s initiatives in mRNA delivery were covered with a focus on their uses in difficult to treat diseases, including cancers. Preclinical data were presented for each of the technologies and where sufficiently advanced, plans for clinical studies as well as early clinical data. The meeting covered the work in progress in this exciting area and highlighted some key technologies to look out for in the future.

KW - nanomedicines

KW - drug delivery

KW - siRNA

KW - mRNA

KW - DNA

KW - proteins

KW - lipid nanoparticles

KW - liposomes

KW - viral vectors

KW - endocytosis

U2 - 10.3390/pharmaceutics11050210

DO - 10.3390/pharmaceutics11050210

M3 - Article

VL - 11

JO - Pharmaceutics

T2 - Pharmaceutics

JF - Pharmaceutics

SN - 1999-4923

IS - 5

M1 - 210

ER -

Wahlich J, Desai A, Greco F, Hill K, Jones AT, Mrsny R et al. Nanomedicines for the delivery of biologics. Pharmaceutics. 2019 May 3;11(5). 210. https://doi.org/10.3390/pharmaceutics11050210